In 1932 when Lady Meherbai Tata died of leukaemia, after treatment abroad, Sir Dorab Tata was determined to establish similar facilities for the treatment of Cancer in India, initially planned for with a Radium Institute in Bombay. Sir Dorab unfortunately died in 1932. Such was the commitment he made that the Trustees of the Sir Dorab Tata Trust, along with various outstanding Cancer specialists committed themselves in 1935 to the establishment of the centre that would benefit the Nation with a more lasting value than the usual philanthropy. Out of this humanitarian concept and commitment from the House of Tatas was born the nucleus of a Hospital, in 1941, called the TATA MEMORIAL HOSPITAL.
The Tata Memorial Hospital was initially commissioned by the Sir Dorabji Tata Trust on 28 February 1941 as a center with enduring value and a mission for concern for the Indian people. In 1952 the Indian Cancer Research Centre was established as a pioneer research institute for basic research - later called the Cancer Research Institute (CRI). In 1957 the Ministry of Health temporarily took over the Tata Memorial Hospital. The transfer of the administrative control of the Tata Memorial Centre (Tata Memorial Hospital and Cancer Research Institute) to the Department of Atomic Energy in 1962 was the next major milestone. This was due to the foresight and the vision of Dr. Homi Bhabha, who envisaged the major role that radiation would play in cancer treatment - from imaging to staging and actual therapy. The TMH and CRI merged as the two arms of the Tata Memorial Centre (TMC) in 1966 represented a classic example of private philanthropy augmented by Government support, with a mandate for Service, Education and Research in Cancer.
The TMC, a Grant-in-Aid institution of the DAE, GOI, now comprises of nine centres - the main Tata Memorial Hospital (TMH) in Mumbai; the Advanced Centre for Treatment, Research & Education in Cancer(ACTREC) at Kharghar, Navi Mumbai; the Centre for Cancer Epidemiology (CCE)at Kharghar, Navi Mumbai; the Homi Bhabha Cancer Hospital & Research Centre (HBCHRC) at Aganampudi, Visakhapatnam; the Homi Bhabha Cancer Hospital (HBCH) at Sangrur, Punjab; the Dr. Bhubaneswar Borooah Cancer Institute (BBCI) at Guwahati; the Homi Bhabha Cancer Hospital at Varanasi; the Homi Bhabha Cancer Hospital & Research Centre (HBCHRC) at Mohali, Punjab. The Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC) at Banaras Hindu University (BHU), Varanasi.
The important aim of CRS & DAE-CTC, Tata Memorial Centre has been to propagate and promote practice of evidence based medicine especially in cancer. In this regard Evidence Based Management meetings were started about a decade and half ago. The philosophy behind the meeting was to identify and answer focused questions relevant to oncology practice in India. National faculties and International faculty members are invited each year who are experts in their field of oncology. The deliberation which typically goes on for 2-4 days includes talk on a particular topic in context with the Indian scenario. This meeting coincides with the “Hospital Day Celebration” of the Institute. The EBM meeting is a much awaited event in the oncology conference calendar.
Over the years, the EBM meetings have covered the following topics:
|2003||Evidence based management of common cancers in India Breast, Head and Neck and Colorectal|
|2004||Addressing burning issues Thoracic, Bone and soft tissue and Pediatric solid tumors|
|2005||Challenges in the practice of evidence based oncology in a developing country (ESTRO / TMH)|
|2006||Addressing special issues Critical care, HIV and cancer, Endocrine cancers and Diagnostic pathology|
|2007||Tobacco control and Lung cancer|
|2008||Evidence based management of cancers in India CNS tumors, Molecular diagnostics and Interventional Radiology|
|2009||a) Guidelines for Complications of Cancer Treatment – GI, Thoracic, Breast & Soft tissue Head and Neck Oncology & Plastic and Reconstructive Surgery b) Molecular Imaging and PET-CT in Cancer|
|2010||Aggressive Non Hodgkin’s Lymphoma Urological Cancers|
|2011||Acute Lukemia Bone and Soft Tissue Tumors Colorectal Cancers|
|2012|| a) Head and Neck Cancers|
b) Hodgkin’s Lymphoma
c) Infections & Cancer
|2013|| a) Thoracic & Foregut Cancers|
b) Multiple Myeloma
|2014|| a) PerioperativeCare: Improving Outcomes After Surgery|
b) Oncologic Imaging: A Multidisciplinary Perspective
|2015|| a) Modern Radiation Oncology Practice|
b) Molecular Haematology: Laboratory Testing for Myeloid Malignancies c) Cardio Oncology: A new focus in Cancer Care
|2016||TMC Platinum Jubilee Celebrations 1st Event – EBM 2016 “A Conference of New Ideas in Cancer - Challenging Dogmas”|
|2017||TMC Platinum Jubilee Celebrations 2nd Event entitled- Healthcare: A Commodity Or Basic Human Need?|
|2017||TMC Platinum Jubilee Celebrations 3rd Event – EBM 2017- “From Controversy to Consensus Shaping Indian National Cancer Policy”|
|2018|| a) Pre - EBM CME: Recent advances in Head and Neck pathology|
b) Head and Neck Cancers
c) Cancer Immunotherapy
d) Paediatric Solid Tumours
|2019|| a) Bioinformatics for Molecular Pathologists – A hands on workshop!! |
b) Clinical Genomics in Hemato-Oncology
c) Preconference Workshop - Contouring and planning SBRT for Pancreatic and Liver cancer
d) Hepato-Pancreato-Biliary Malignancies
e) Cancer associated thrombosis
|2020|| a) Contemporary Management in Neuro-Oncology |
b)Pre-conference: Masterclass in Neurosurgical Oncology 2020
c)Current Concepts and Controversies In Palliative Medicine
d)Pre-Conference Workshop On Research Methods In Palliative Medicine
e) Urological Cancers: A Decade of Transformation
We, at the Tata Memorial Hospital are bestowed with the widest range of patients in large numbers and finest laboratory support. A unique centre ' Clinical Research Secretariat ' was commissioned in 1997 to temper the vast data generated from clinics/laboratory and draw meaningful conclusions with clinical endpoints.
The CRS offered a wide range of services from collection, maintenance, quality control & analysis of data to design & execution of prospective trials of importance to the institute and nation. The primary aim was to generate easily testable hypothesis from focused retrospective analysis or laboratory studies. To test novel avenues with survival or quality of life end points in observational studies or randomized trials. To support mega-trials from multiple centres spread all over India. To rethink on more technology in patient care and challenging dogma with appropriate clinical studies. To collate published evidence by Meta-analysis to define the state of art treatment.